JDRF T1D Fund is a non-profit venture philanthropy organization focused on early-stage investments in type 1 diabetes (T1D) treatments, preventions, and cures. Based in New York, the fund targets innovative life sciences companies developing solutions for T1D, with investments spanning various stages from seed to Series D rounds.
The fund's portfolio includes notable companies such as Abata Therapeutics, Bigfoot Biomedical, and GentiBio. JDRF T1D Fund leverages its expertise in T1D research and treatment to support portfolio companies, aiming to accelerate the development of breakthrough therapies and technologies for the estimated 1.7 million people living with T1D globally.
Jdrf T1D Fund - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments30
Current Portfolio Count18
Total Portfolio Exits1
Top Investment Stages
Series A10 (37.0%)
Series Unknown6 (22.2%)
Series B5 (18.5%)
Seed3 (11.1%)
Series C3 (11.1%)
Stage Mix
Series A 37%Series Unknown 22%Series B 19%Seed 11%Series C 11%
Concentration shown as share of disclosed investments by stage.
Jdrf T1D Fund - Classification
- Also Known As
- Jdrf T1D Fund LLC
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end